Official title and information are available only for Plus and Premium subscribers.
Patent Pending Herpes simplex virus is considered as a potential therapy for cancer and has been extensively clinically tested to assess its oncolytic (cancer killing) ability.[49] Interim overall survival data from Amgen's phase 3 trial of a genetically-attenuated herpes virus suggests efficacy against melanoma.
To see the additional information details please login and subscribe to a Plus or Premium account.
